Wallach, Joshua D. http://orcid.org/0000-0002-2816-6905
Rhee, Taeho Greg
Edelman, E. Jennifer
Shah, Nilay D.
O’Malley, Stephanie S.
Ross, Joseph S.
Article History
Received: 19 October 2020
Accepted: 14 February 2021
First Online: 5 March 2021
Declarations
:
: In the past 36 months, Dr. Wallach received research support through the Collaboration for Research Integrity and Transparency (CRIT) at Yale University from the Laura and John Arnold Foundation and through the Center for Excellence in Regulatory Science and Innovation (CERSI) at Yale University and the Mayo Clinic (U01FD005938). Dr. Rhee was supported in part by the National Institute on Aging (#T32AG019134) through Yale School of Medicine in the past 36 months. Rhee is currently funded by the National Institute of Mental Health (#R21MH117438) and the Institute for Collaboration on Health, Intervention, and Policy (InCHIP) at the University of Connecticut. In the past 36 months, Dr. Edelman has received research support through the NIH (National Institute on Drug Abuse (NIDA), National Cancer Institute (NCI), National Institute on Alcohol Abuse and Alcoholism (NIAAA), and National Institute of Mental Health (NIMH)). In the past 36 months, Dr. Shah has received research support through Mayo Clinic from the Food and Drug Administration to establish Yale-Mayo Clinic Center for Excellence in Regulatory Science and Innovation (CERSI) program (U01FD005938) and through National evaluation center for health technologies (NESTcc) from the Food and Drug Administration; the Centers of Medicare and Medicaid Innovation under the Transforming Clinical Practice Initiative (TCPI); the Agency for Healthcare Research and Quality (R01HS025164; R01HS025402; R03HS025517; K12HS026379); the National Heart, Lung and Blood Institute of the National Institutes of Health (NIH) (R56HL130496; R01HL131535); the National Science Foundation; and the Patient Centered Outcomes Research Institute (PCORI) to develop a Clinical Data Research Network (LHSNet). Dr. O’Malley reports having been a consultant or advisory board member for Alkermes, Amygdala, Dicerna, and Opiant, a member of the American Society of Clinical Psychopharmacology Alcohol Clinical Trials Initiative (ACTIVE) supported by Alkermes, Amygdala Neurosciences, Arbor Pharmaceuticals, Dicerna, Ethypharm, Indivior, Lundbeck, Mitsubishi, and Otsuka; receiving donated study medications for NIH sponsored research from Astra Zeneca, Novartis; DSMB Member for NIDA Clinical Trials Network (Emmes). Dr. Ross received research support through Yale from Johnson and Johnson to develop methods of clinical trial data sharing, from Medtronic, Inc. and the Food and Drug Administration (FDA) to develop methods for postmarket surveillance of medical devices (U01FD004585), from the Centers of Medicare and Medicaid Services (CMS) to develop and maintain performance measures that are used for public reporting, from the FDA to establish a Center for Excellence in Regulatory Science and Innovation (CERSI) at Yale University and the Mayo Clinic (U01FD005938), from the Blue Cross Blue Shield Association to better understand medical technology evaluation, and from the Agency for Healthcare Research and Quality (R01HS022882).
Free to read: This content has been made available to all.